CW June 2006
Volume 15Issue Number 6 June 2006 ISSN 10593802 Orphan Drug Designation for CA4PA vascular disrupting agent, CA4P, receives Orphan Drug status from the US Food and Drug Administration for the treatment of ovarian cancer.
Go to Previous Page Source & Additional Reading Cancer Watch October 2005; December 2004 Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW June 2006Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
